An apparatus and method for non-invasive treatment in lieu of cosmetic surgery is disclosed. The apparatus comprises a combination of a high and low voltage pulse generators connected to two or more electrodes placed on a treatment site of the patient's body. high voltage pulses, delivered to the electrodes, create an electric field that kills subcutaneous fat cells. low voltage pulses, delivered to the same or individual electrodes provide transcutaneous electrical nerve stimulation (tens), blocking the signals of discomfort or pain that may arise from the high voltage pulsing.

Patent
   RE42835
Priority
Aug 17 2000
Filed
Oct 01 2009
Issued
Oct 11 2011
Expiry
Aug 17 2021

TERM.DISCL.
Assg.orig
Entity
Large
95
152
all paid
17. A method for reducing subcutaneous fat deposits in a treatment volume by electroporation with improved patient comfort, said method comprising:
applying a plurality of electroporation electric field pulses to the treatment volume to induce subcutaneous fat cell death by electroporation; and
applying a plurality of tens electric field pulses at least to the treatment volume to improve patient comfort by transcutaneous electric nerve stimulation at least in the treatment volume.
1. An apparatus for reducing subcutaneous fat deposits by electroporation with improved comfort of patients comprising:
an applicator comprising two sets of electrodes, the first and the second, said first set of electrodes are high voltage electrodes adapted for engaging the skin of a patient and applying a high amplitude pulsed electric field to the area of skin and the subcutaneous volume of tissues to be treated by electroporation, said second set of electrodes adapted for transcutaneous electrical nerve stimulation of the skin and the volume of the subcutaneous tissue over an area generally larger than the area of electroporation treatment;
a generator of high voltage pulses for applying pulsed electric field to the first set of electrodes, said pulses generating an electric field above the upper electroporation limit for subcutaneous fat cells in the volume of the subcutaneous tissue to be treated;
a generator for generating low voltage pulses for applying pulsed electric field to the second set of electrodes, said amplitude of the electric field is adapted for Transcutaneous Electrical Nerve Stimulation (tens) of the skin and subcutaneous tissue;
a synchronizing circuit connected to said high and said low voltage pulse generators and providing triggering of the high voltage pulses with a controllable delay after the tens pulses, and
connectors connecting said generators of high and low voltage electrical pulses with corresponding high and low voltage electrodes.
12. An apparatus for reducing subcutaneous fat deposits in a predetermined treatment volume beneath a predetermined area of a patient's skin by electroporation with improved comfort for the patient, said apparatus comprises:
first and second electrode sets, wherein said first electrode set comprises:
at least a pair of electroporation electrodes, said electroporation electrodes being provided for applying a pulsed electric field to the predetermined area of skin and the subcutaneous volume of tissues; and
wherein said second electrode set comprises:
at least a pair of tens electrodes, said tens electrodes being configured for transcutaneous electrical stimulation of the patient over a tissue volume including at least the predetermined treatment volume;
a generator of high voltage pulses for applying a pulsed electric field to the predetermined area via said first electrode set, said pulses generating an electric field above the upper electroporation limit for subcutaneous fat cells in the volume of the subcutaneous tissue to be treated;
a generator for generating low voltage pulses for applying a pulsed electric field to the predetermined area via said second electrode set, wherein the amplitude of the low voltage electric field is chosen to provide transcutaneous electrical nerve stimulation (tens) of the nerves of the skin and subcutaneous tissue in an area larger than the predetermined area;
a synchronizing circuit connected to said high and said low voltage pulse generators and providing triggering of the high voltage pulses with a controllable delay after the tens pulses, and
connectors connecting said generators of high and low voltage electrical pulses with corresponding electroporation and tens electrodes.
11. A method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients comprising:
providing an applicator comprising first and second sets of electrodes, wherein first set of electrodes are high voltage electrodes are configured for engaging the skin of a patient and applying a high amplitude pulsed electric field to the area of skin and the subcutaneous volume of tissues to be treated by electroporation and wherein said second set of electrodes are configured for transcutaneous electrical nerve stimulation of the skin and the volume of the subcutaneous tissue over an area generally larger than the area of electroporation treatment;
providing a generator of high voltage pulses for applying pulsed electric field to the first set of electrodes, said pulses generating an electric field above the upper electroporation limit for subcutaneous fat cells in the volume of the subcutaneous tissue to be treated;
providing a generator for generating low voltage pulses for applying pulsed electric field to the second set of electrodes, said amplitude of the electric field providing transcutaneous electrical nerve stimulation (tens) of the skin and subcutaneous tissue;
providing a synchronizing circuit connected to said high and said low voltage pulse generators and providing triggering of the high voltage pulses with a controllable delay after the tens pulses;
connecting said generators of high and low voltage electrical pulses with corresponding high and low voltage electrodes; and
applying tens pulses via said second set of electrodes to the area in and around of the area to be treated and high voltage pulses via said first set of electrodes with an amplitude sufficient to cause death to subcutaneous fat cells.
2. An apparatus according to claim 1 wherein the two sets of electrodes in the applicator share at least some electrodes to which both the high voltage pulses for electroporation and low voltage pulses for tens are applied.
3. An apparatus according to claim 1 wherein said high voltage pulses have duration in a range of 10 microseconds to 1 millisecond.
4. An apparatus according to claim 1 wherein the amplitude of the electric field applied to the treated volume falls in a range of 20 Volt/mm to 2000 Volt/mm.
5. An apparatus according to claim 1 wherein said delay of the high voltage pulses relatively to the tens pulses falls into the time range of 0 to 1.5 milliseconds.
6. An apparatus according to claim 1 wherein both low and high voltage pulses are electrically balanced in such a manner that in average no direct current is passing through the treatment volume.
7. An apparatus according to claim 1 wherein high voltage pulses are rectangular balanced.
8. An apparatus according to claim 1 wherein said low voltage pulses have duration in a range of 10 to 200 microseconds.
9. An apparatus according to claim 1 wherein said low voltage pulses have repetition rate in a range of 4 to 120 Hertz.
10. An apparatus according to claim 1 wherein said low voltage pulses have amplitude in the range from 10 to 100 V.
13. An apparatus according to claim 12 wherein the two sets of electrodes in the applicator share at least some electrodes to which both the high voltage pulses for electroporation and low voltage pulses for tens are applied.
14. An apparatus according to claim 12 wherein said delay of the high voltage pulses relatively to the tens pulses falls into the time range of 0 to 1.5 milliseconds.
15. An apparatus according to claim 12 wherein both low and high voltage pulses are electrically balanced in such a manner that in average no direct current is passing through the treatment volume.
16. An apparatus according to claim 12 wherein high voltage pulses are rectangular balanced.
18. The method of claim 17 wherein the tens electric field is applied to at least the treatment volume prior to application of the electroporation field.
19. The method of claim 17 wherein the applied electroporation and tens pulses are synchronized such that a tens pulse is applied to at least to the treatment volume prior to application of an electroporation pulse.
20. The method of claim 19 wherein application of an electroporation pulse relative to the application of a tens pulse is delayed by a time in the range of about 0 to about 1.5 milliseconds.
21. The method of claim 17 wherein both electroporation and tens pulses are electrically balanced in such a manner that in average no direct current is passing through the treatment volume.
22. The method of claim 1 wherein the electroporation pulses are rectangularly balanced.

where:
    • d=the pulse duration;
    • b=the threshold excitation current density for an infinitely long pulse;
    • I=the threshold excitation current density for a pulse with duration d; and
    • τ=the membrane time constant for a particular excitable tissue.

For sensory nerves in the human skin, τ∇0.5 ms (millisecond) and b∇2 (mA/cm2). The strength-duration curves illustrating the Blair equation for different excitable tissues are shown in FIG. 2. The middle curve in the figure shows the strength-duration curve for the excitation of sensory nerves which are located in the skin and are responsible for the sensation of discomfort during electroporation procedure. The curves illustrate the relative increase in the threshold of excitation with the decrease in the duration of the electrical pulses for different excitable tissues. As can be seen from the middle curve, the threshold of excitation of sensory nerves (the middle curve of the three shown on the Figure) for 10-20 microsecond pulses is 20-50 times higher than that for 1 ms pulses. Electroporation is observed where the applied pulses have a duration of 10 microseconds and longer. To preserve the ability of EP pulses to kill cells but at the same time create as low of a sensation as possible in the patient, relatively shorter multiple pulses are preferred to long EP pulses. To preserve the ability to excite nerve cells in the extended area around electrodes, which is especially important when the same electrodes are used for both type of pulsing, the TENS pulses, having lower amplitudes than the EP pulses, may be selected to be significantly longer than the EP pulses, but at lower amplitudes than the EP pulses.

An excitation threshold of a nerve depends not only upon the duration of the stimulating pulse but also upon the immediate local excitation history of the nerve. FIG. 3 shows a plot of an “action potential,” which is a potential difference between the inner and the outer sides of the cell membrane as a function of time during an excitation. Normally, when a cell is at rest, the potential difference (or as commonly called, the voltage) across the membrane, called a “resting potential,” is about −90 mV. When an electric stimulus causes local depolarization of the membrane (decreases the negative potential across the membrane) to a value about −60 mV, called a “resting threshold”, the cell gets excited and an action potential starts propagating from the site of excitation along the nerve fiber. That is, as the potential difference across the membrane exceeds the resting threshold, a sudden change in the permeability of the membrane for sodium and potassium ions (Na+ and K+, respectively) occurs that causes rapid movement of these ions across the cell membrane, resulting in the action potential. The action potential propagates along the cell and depending on where it goes and where it comes from, carries different signals in the body.

As can be seen from the FIG. 3, over a period of time of about 1.5 ms the potential across the cell membrane rapidly increases from its resting threshold of about −60 mV to +40 mV and slowly returns back to the resting potential of −90 mV. There is a period of about 0.75 ms after stimulation when the nerve cannot be restimulated at all, no matter how high the stimulus is. This period is called the “absolute refractory period” (the threshold is infinitely high) and generally lasts for approximately 0.75 ms after reaching the peak of the action potential at about +40 mV. The absolutely refractory period is followed by a “relative refractory period”, where a stimulus greater than normal is needed to initiate an action potential. The evolution of the level of the excitation threshold during an action potential is shown in FIG. 3 by a dashed line.

The threshold of excitation of a cell at rest depends not only on the duration of the electrical stimulus but also on the waveform of the stimulus. The threshold for a bipolar pulse, consisting of two parts, a positive one and identical in shape but negative in polarity, is higher than that for a unipolar pulse. The reason for that is that the cell launches an acting potential only when the resting threshold of the excitation is reached. This happens when a change of the electrical charges on both sides of the membrane occurs that depolarizes it from −90 mV to −60 mV. If a bipolar pulse is applied to the cell, only the first half of the pulse causes a depolarization of the cellular membrane that can lead to a firing of an action potential. If the cell is not ready to fire after the first half of the pulse, when the current reverses and begins to flow the other direction in the second half of the pulse, the reversing electric current polarizes the membrane back to the previous level of −90 mV. In other words, all nerves including sensory are less sensitive to bipolar pulses than to unipolar of the same overall duration. Actually, their sensitivity approximately corresponds to that of a unipolar pulse with a half duration.

Bipolar rectangular pulses are known to be very efficient in cell killing by electroporation. Contrary to the sensitivity of excitable cells to electric stimulus, both directions of the electrical field, that is, positive (+) and negative (−), are equally efficient in creating pores in cellular membranes. This efficiency results because electroporation is a process is related to the difference in the energy of the porous and non-porous membrane in the presence of an electric field. This energy difference depends on the square of the amplitude (or strength) of the electric field (i.e., E2) and does not depend on the sign or polarity (+ or −) of the electric field.

From a practical stand point, however, applying balanced pulses during in-vivo electroporation treatment has one important advantage. Contrary to unipolar pulsing, that carries a direct current component into the treated tissue and creates undesired electrolytic effects on the interface of the electrodes and tissues, bipolar pulsing is free from these drawbacks. With the bipolar pulsing problems such as metal depositions from the electrodes or chemical decomposition of tissue during treatment are largely if not completely avoided.

These advantageous properties of balanced pulses, namely, lower excitability of the nerve cells, high efficiency in cell killing and freedom from electrolytic effects, make using rectangular bipolar balanced pulses a preferred mode for electroporation pulsing in the current invention. Technically, balancing of two pulses of the opposite polarities may be easily achieved by using a pulse generator having a direct current blocking capacitor electrically coupled in series to the transcutaneous electrodes.

The time diagram of the pulses applied to the electrodes are shown in FIGS. 4a and 4b. In FIGS. 4a and 4b voltage is plotted as a function of time for the In FIGS. 4a and 4b voltage is plotted as a function of time for the EP pulses designated for cell killing (the upper curve in each of FIGS. 4a and 4b), and the TENS pulses applied for mitigation of discomfort of the patient (the lower curve in each of FIGS. 4a and 4b). In FIG. 4a bipolar balanced rectangular EP pulses and exponential balanced TENS pulses are shown. This is the preferred embodiment for the EP—TENS treatment of the current invention. FIG. 4b shows unipolar exponential pulses. The time delay Δt between preselected TENS and synchronized EP is introduced into pulsing to ensure that the high voltage pulses are applied during the refractory state of the surrounding nerves to minimize discomfort of the patient. This time delay falls into a range of 0 to about 1.5 milliseconds and can be selected during the treatment procedure for the best comfort of the patient

The EP pulses depend upon the size of the electrodes and the distance between them and may be in the range of about 50 V to about 5000 V with a duration of about 10 microseconds to about 1.0 milliseconds. The TENS pulses may have duration of about 20 to about 1000 microseconds.

FIGS. 5-7 show different embodiments of applicators for combining EP and TENS treatment. In FIG. 5 two large pad electrodes, positive 50 and negative 52, provide TENS treatment for the area 54 of the skin 56 between the pads 50 and 52. One electrode of the EP generator, exemplary positive, is connected to pad 50, while the second, negative polarity electrode of the generator is connected to a needle electrode 58, thereby providing EP treatment in the area between the pad electrodes 50 and 52. In this embodiment, the pads would be applied to the skin and held there in a known manner, while the needle electode 58 would me manually or mechanically manipulated as desired in the area between the pads.

In FIG. 6 a multi-needle applicator 60 is shown having a hand piece 62. Handpiece 62 is attached to a frame 64 of a desired configuration carrying a an array of needle electrodes 66 comprising a plurality of needle electrodes 68 and 70. Some of the needle electrodes, those designated as electrodes 68, and which are primarily on the periphery of the array, may be connected to a TENS generator to function as TENS electrodes alone, while needle electrodes 70 may be connected to both the TENS and EP generators to function as both EP and TENS electrodes. It will be observed that placing the combined EP and TENS electrodes 70 inside the periphery of the TENS only electrodes 68 that a TENS coverage area exceeding the EP coverage area is achieved. The appropriate connectors 72 and 74 are used to connect the applicator 60, and thus the needle electrodes 68 and 70, to the EP and TENS generators.

FIG. 7 shows a two electrode applicator 80 including a handle 82. In this embodiment of the present invention, both electrodes 84 and 86 are common for EP and TENS processes. For this embodiment of the applicator the TENS pulses should be selected to be generally longer in duration and higher in the amplitude while the EP pulses should be short and multiple with a relatively long delay time. This choice of operating parameters of the system will ensure that the TENS treatment is provided to the whole area where the EP pulses can possibly excite the sensory nerves.

In operation, apparatus in accord with the present invention will include using TENS electrodes to create an anesthetic effect in at least the treatment volume and preferentially in a larger volume of patient tissue that includes the treatment volume. This anesthetic effect can be created by application of TENS pulses to the patient. Preferably subsequently to the creation of the anesthetic effect, EP pulses can be applied to the treatment, resulting in the death of some or all of the subcutaneous fat cells in the treatment volume. Other patient tissue treatment volumes can then be treated similarly. In this manner then, the present invention provides apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients.

The present invention has been described in language more or less specific as to the apparatus and method features. It is to be understood, however, that the present invention is not limited to the specific features described, since the apparatus and method herein disclosed comprise exemplary forms of putting the present invention into effect. The invention is, therefore, claimed in any of its forms or modifications within the proper scope of the appended claims appropriately interpreted in accordance with the doctrine of equivalency and other applicable judicial doctrines.

Jaafar, Ali, Chornenky, Victor

Patent Priority Assignee Title
10092346, Jul 20 2010 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
10117707, Apr 29 2008 Virginia Tech Intellectual Properties, Inc System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
10154874, Apr 29 2008 Virginia Tech Intellectual Properties, Inc Immunotherapeutic methods using irreversible electroporation
10201380, Jan 31 2014 ZELTIQ AESTHETICS, INC Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments
10238447, Apr 29 2008 Virginia Tech Intellectual Properties, Inc System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
10245098, Apr 29 2008 Virginia Tech Intellectual Properties, Inc Acute blood-brain barrier disruption using electrical energy based therapy
10245105, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Electroporation with cooling to treat tissue
10272178, Apr 29 2008 Virginia Tech Intellectual Properties, Inc Methods for blood-brain barrier disruption using electrical energy
10286108, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
10292755, Apr 09 2009 Virginia Tech Intellectual Properties, Inc. High frequency electroporation for cancer therapy
10292859, Sep 26 2006 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
10383787, May 18 2007 Zeltiq Aesthetics, Inc. Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue
10448989, Apr 09 2009 Virginia Tech Intellectual Properties, Inc High-frequency electroporation for cancer therapy
10470822, Apr 29 2008 Virginia Tech Intellectual Properties, Inc System and method for estimating a treatment volume for administering electrical-energy based therapies
10471254, May 12 2014 Virginia Tech Intellectual Properties, Inc Selective modulation of intracellular effects of cells using pulsed electric fields
10524956, Jan 07 2016 ZELTIQ AESTHETICS, INC Temperature-dependent adhesion between applicator and skin during cooling of tissue
10537379, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
10555831, May 10 2016 ZELTIQ AESTHETICS, INC Hydrogel substances and methods of cryotherapy
10568759, Aug 19 2014 ZELTIQ AESTHETICS, INC Treatment systems, small volume applicators, and methods for treating submental tissue
10575890, Jan 31 2014 ZELTIQ AESTHETICS, INC Treatment systems and methods for affecting glands and other targeted structures
10675176, Mar 19 2014 ZELTIQ AESTHETICS, INC Treatment systems, devices, and methods for cooling targeted tissue
10675178, Aug 21 2007 ZELTIQ AESTHETICS, INC Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
10682297, May 10 2016 ZELTIQ AESTHETICS, INC Liposomes, emulsions, and methods for cryotherapy
10694972, Dec 15 2014 Virginia Polytechnic Institute and State University; Virginia Tech Intellectual Properties, Inc Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
10702326, Jul 15 2011 Virginia Tech Intellectual Properties, Inc Device and method for electroporation based treatment of stenosis of a tubular body part
10702337, Jun 27 2016 GALVANIZE THERAPEUTICS, INC Methods, apparatuses, and systems for the treatment of pulmonary disorders
10765552, Feb 18 2016 ZELTIQ AESTHETICS, INC Cooling cup applicators with contoured heads and liner assemblies
10806500, Jan 31 2014 Zeltiq Aesthetics, Inc. Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments
10828085, Apr 29 2008 Virginia Tech Intellectual Properties, Inc Immunotherapeutic methods using irreversible electroporation
10828086, Apr 29 2008 Virginia Tech Intellectual Properties, Inc Immunotherapeutic methods using irreversible electroporation
10912599, Jan 31 2014 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
10935174, Aug 19 2014 ZELTIQ AESTHETICS, INC Stress relief couplings for cryotherapy apparatuses
10939958, Jun 27 2016 GALVANIZE THERAPEUTICS, INC Methods, apparatuses, and systems for the treatment of pulmonary disorders
10952891, May 13 2014 ZELTIQ AESTHETICS, INC Treatment systems with adjustable gap applicators and methods for cooling tissue
10959772, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Blood-brain barrier disruption using electrical energy
11076879, Apr 26 2017 ZELTIQ AESTHETICS, INC Shallow surface cryotherapy applicators and related technology
11154418, Oct 19 2015 ZELTIQ AESTHETICS, INC Vascular treatment systems, cooling devices, and methods for cooling vascular structures
11179269, Sep 26 2006 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
11219549, Sep 26 2006 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
11224536, Apr 30 2009 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
11254926, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
11272979, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
11291606, May 18 2007 Zeltiq Aesthetics, Inc. Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue
11311329, Mar 13 2018 Virginia Polytechnic Institute and State University; Virginia Tech Intellectual Properties, Inc; VIRGINA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
11369433, Jun 27 2016 GALVANIZE THERAPEUTICS, INC Methods, apparatuses, and systems for the treatment of pulmonary disorders
11382681, Apr 09 2009 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
11382790, May 10 2016 ZELTIQ AESTHETICS, INC Skin freezing systems for treating acne and skin conditions
11395760, Nov 09 2006 Zeltiq Aesthetics, Inc. Tissue treatment methods
11406820, May 12 2014 Virginia Tech Intellectual Properties, Inc Selective modulation of intracellular effects of cells using pulsed electric fields
11446175, Jul 31 2018 ZELTIQ AESTHETICS, INC Methods, devices, and systems for improving skin characteristics
11452634, Apr 30 2009 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
11453873, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Methods for delivery of biphasic electrical pulses for non-thermal ablation
11583438, Aug 21 2007 ZELTIQ AESTHETICS, INC Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
11607271, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
11607537, Dec 05 2017 Virginia Tech Intellectual Properties, Inc Method for treating neurological disorders, including tumors, with electroporation
11638603, Apr 09 2009 Virginia Tech Intellectual Properties, Inc Selective modulation of intracellular effects of cells using pulsed electric fields
11655466, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Methods of reducing adverse effects of non-thermal ablation
11707629, May 28 2009 AngioDynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
11723710, Nov 17 2016 AngioDynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
11737810, Apr 29 2008 Virginia Tech Intellectual Properties, Inc Immunotherapeutic methods using electroporation
11779395, Sep 28 2011 AngioDynamics, Inc. Multiple treatment zone ablation probe
11819257, Jan 31 2014 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
11890046, Apr 29 2008 Virginia Tech Intellectual Properties, Inc System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
11903690, Dec 15 2014 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
11925405, Mar 13 2018 Virginia Tech Intellectual Properties, Inc Treatment planning system for immunotherapy enhancement via non-thermal ablation
11931096, Oct 13 2010 AngioDynamics, Inc. System and method for electrically ablating tissue of a patient
11950835, Jun 28 2019 AngioDynamics, Inc Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
11952568, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of biphasic electrical pulses for non-thermal ablation
11957405, Jun 13 2013 AngioDynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
11974800, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
11986421, Sep 26 2006 ZELTIQ AESTHETICS, INC Cooling devices with flexible sensors
12059197, Apr 29 2008 Virginia Tech Intellectual Properties, Inc. Blood-brain barrier disruption using reversible or irreversible electroporation
12070411, Apr 28 2006 Zeltiq Aesthetics, Inc. Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells
12102376, Feb 08 2012 AngioDynamics, Inc. System and method for increasing a target zone for electrical ablation
12102557, Jul 31 2018 Zeltiq Aesthetics, Inc. Methods, devices, and systems for improving skin characteristics
12114911, Aug 28 2014 AngioDynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring
8676338, Jul 20 2010 ZELTIQ AESTHETICS, INC Combined modality treatment systems, methods and apparatus for body contouring applications
8702774, Apr 30 2009 Zeltiq Aesthetics, Inc.; ZELTIQ AESTHETICS, INC Device, system and method of removing heat from subcutaneous lipid-rich cells
9314368, Jan 25 2010 ZELTIQ AESTHETICS, INC Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods
9375345, Sep 26 2006 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
9408745, Aug 21 2007 ZELTIQ AESTHETICS, INC Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
9457183, Jun 15 2011 Tripep AB Injection needle and device
9545523, Mar 14 2013 ZELTIQ AESTHETICS, INC Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
9598691, Apr 29 2008 Virginia Tech Intellectual Properties, Inc Irreversible electroporation to create tissue scaffolds
9655770, Jul 13 2007 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
9737434, Dec 17 2008 Zeltiq Aestehtics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
9757196, Sep 28 2012 AngioDynamics, Inc. Multiple treatment zone ablation probe
9844460, Mar 14 2013 ZELTIQ AESTHETICS, INC Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
9844461, Jan 25 2010 ZELTIQ AESTHETICS, INC Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants
9861421, Jan 31 2014 ZELTIQ AESTHETICS, INC Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
9861520, Apr 30 2009 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
9867652, Apr 29 2008 Virginia Tech Intellectual Properties, Inc Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
9888956, Jan 22 2013 AngioDynamics, Inc Integrated pump and generator device and method of use
9895189, Jun 13 2013 AngioDynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
D777338, Mar 20 2014 ZELTIQ AESTHETICS, INC Cryotherapy applicator for cooling tissue
Patent Priority Assignee Title
1653819,
4016886, Nov 26 1974 The United States of America as represented by the United States Energy Method for localizing heating in tumor tissue
4226246, May 27 1977 Carba Societe Anonyme Apparatus for maintaining the negative potential of human, animal, and plant cells
4262672, Jan 02 1978 Acupuncture instrument
4407943, Dec 16 1976 MILLIPORE INVESTMENT HOLDINGS LIMITED, A CORP OF DE Immobilized antibody or antigen for immunoassay
4810963, Apr 03 1984 Public Health Laboratory Service Board Method for investigating the condition of a bacterial suspension through frequency profile of electrical admittance
4907601, Jun 15 1988 Etama AG Electrotherapy arrangement
4946793, May 08 1987 Electropore, Inc.; ELECTROPORE, INC , A DE CORP Impedance matching for instrumentation which electrically alters vesicle membranes
5019034, Jan 21 1988 MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE, A CORP OF MA Control of transport of molecules across tissue using electroporation
5052391, Oct 22 1990 R F P , INC High frequency high intensity transcutaneous electrical nerve stimulator and method of treatment
5058605, Feb 22 1989 Ceske vysoke uceni technicke Method and device for the controlled local, non-invasive application of DC pulses to human and animal tissues
5098843, Jun 04 1987 Apparatus for the high efficiency transformation of living cells
5134070, Jun 04 1990 ALLAN PIASETZKI, GREGORY Method and device for cell cultivation on electrodes
5173158, Jul 22 1991 Apparatus and methods for electroporation and electrofusion
5193537, Jun 12 1990 ZOLL Medical Corporation Method and apparatus for transcutaneous electrical cardiac pacing
5273525, Aug 13 1992 GENETRONICS, INC Injection and electroporation apparatus for drug and gene delivery
5283194, Jul 22 1991 Apparatus and methods for electroporation and electrofusion
5318563, Jun 04 1992 RUTH MALIS, REPRESENTATIVE , ESTATE OF LEONARD I MALIS, DECEASED Bipolar RF generator
5328451, Aug 15 1991 Board of Regents, The University of Texas System Iontophoretic device and method for killing bacteria and other microbes
5389069, Jan 21 1988 Massachusetts Institute of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
5403311, Mar 29 1993 Boston Scientific Scimed, Inc Electro-coagulation and ablation and other electrotherapeutic treatments of body tissue
5425752, Nov 25 1991 Method of direct electrical myostimulation using acupuncture needles
5439440, Apr 01 1993 OncoSec Medical Incorporated Electroporation system with voltage control feedback for clinical applications
5458625, May 04 1994 Transcutaneous nerve stimulation device and method for using same
5533999, Aug 23 1993 REFRACTEC INC Method and apparatus for modifications of visual acuity by thermal means
5536240, Aug 12 1992 VENTURE LENDING & LEASING, INC Medical probe device and method
5575811, Jul 08 1993 PROJECT TROJAN INTELLECTUAL PROPERTY ACQUISITION, LLC; AUSLO RESEARCH LLC Benign prostatic hyperplasia treatment catheter with urethral cooling
5626146, Dec 18 1992 British Technology Group Limited Electrical impedance tomography
5634899, Aug 20 1993 VENTION MEDICAL ADVANCED COMPONENTS, INC Simultaneous cardiac pacing and local drug delivery method
5674267, Mar 30 1993 Centre National de la Recherche Scientifique Electric pulse applicator using pairs of needle electrodes for the treatment of biological tissue
5702359, Apr 01 1993 OncoSec Medical Incorporated Needle electrodes for mediated delivery of drugs and genes
5720921, Mar 10 1995 MaxCyte, Inc Flow electroporation chamber and method
5778894, Apr 18 1996 FD MANAGEMENT, INC Method for reducing human body cellulite by treatment with pulsed electromagnetic energy
5782882, Nov 30 1995 Koninklijke Philips Electronics N V System and method for administering transcutaneous cardiac pacing with transcutaneous electrical nerve stimulation
5800378, Aug 12 1992 Vidamed, Inc. Medical probe device and method
5810762, Apr 10 1995 OncoSec Medical Incorporated Electroporation system with voltage control feedback for clinical applications
5836905, Jun 20 1994 Apparatus and methods for gene therapy
5843026, Aug 12 1992 Vidamed, Inc. BPH ablation method and apparatus
5873849, Apr 24 1997 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
5919142, Jun 22 1995 BTG International Limited Electrical impedance tomography method and apparatus
5947889, Jan 17 1995 Balloon catheter used to prevent re-stenosis after angioplasty and process for producing a balloon catheter
5983131, Aug 11 1995 Massachusetts Institute of Technology Apparatus and method for electroporation of tissue
5991697, Dec 31 1996 CALIFORNIA, UNIVERSITY OF, REGENTS OF THE, THE Method and apparatus for optical Doppler tomographic imaging of fluid flow velocity in highly scattering media
5999847, Oct 21 1997 Apparatus and method for delivery of surgical and therapeutic agents
6009347, Jan 27 1998 OncoSec Medical Incorporated Electroporation apparatus with connective electrode template
6010613, Dec 08 1995 CELLECTIS S A Method of treating materials with pulsed electrical fields
6016452, Mar 19 1996 Dynamic heating method and radio frequency thermal treatment
6041252, Jun 07 1995 ICHOR MEDICAL SYSTEMS, INC Drug delivery system and method
6055453, Aug 01 1997 OncoSec Medical Incorporated Apparatus for addressing needle array electrodes for electroporation therapy
6068650, Aug 01 1997 OncoSec Medical Incorporated Method of Selectively applying needle array configurations
6085115, May 22 1997 Massachusetts Institute of Technology Biopotential measurement including electroporation of tissue surface
6090106, Jan 09 1996 Gyrus Medical Limited Electrosurgical instrument
6102885, Aug 08 1996 CURVE MEDICAL, LLC Device for suction-assisted lipectomy and method of using same
6106521, Aug 16 1996 United States Surgical Corporation Apparatus for thermal treatment of tissue
6109270, Feb 04 1997 NATIONAL AERONAUTICS AND SPACE ADMINISTRATION, ADMINISTRATOR OF THE Multimodality instrument for tissue characterization
6122599, Feb 13 1998 JONES JAIN, LLP Apparatus and method for analyzing particles
6132419, May 22 1992 Genetronics, Inc. Electroporetic gene and drug therapy
6159163, May 07 1998 Cedars-Sinai Medical Center System for attenuating pain during bone marrow aspiration and method
6208893, Dec 07 1998 OncoSec Medical Incorporated Electroporation apparatus with connective electrode template
6210402, Nov 22 1995 Arthrocare Corporation Methods for electrosurgical dermatological treatment
6212433, Jul 28 1998 Boston Scientific Scimed, Inc Method for treating tumors near the surface of an organ
6216034, Aug 01 1997 OncoSec Medical Incorporated Method of programming an array of needle electrodes for electroporation therapy of tissue
6219577, Apr 14 1998 GMP DRUG DELIVERY, INC Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues
6241702, Aug 12 1992 Vidamed, Inc. Radio frequency ablation device for treatment of the prostate
6261831, Mar 26 1999 The United States of America as represented by the Secretary of the Air; GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE, THE Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat
6278895, Apr 27 1997 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
6300108, Jul 21 1999 Regents of the University of California, The Controlled electroporation and mass transfer across cell membranes
6326177, Aug 04 1999 OLD DOMINION UNIVERSITY RESEARCH FOUNDATION Method and apparatus for intracellular electro-manipulation
6347247, May 08 1998 OncoSec Medical Incorporated Electrically induced vessel vasodilation
6349233, Feb 22 1993 ELA MEDICAL, S A Neuro-stimulation to control pain during cardioversion defibrillation
6351674, Nov 23 1998 Synaptic Corporation Method for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation
6387671, Jul 21 1999 REGENTS OF THE UNIVERSITY OF CALIFORNIA,THE Electrical impedance tomography to control electroporation
6403348, Jul 21 1999 Regents of the University of California, The Controlled electroporation and mass transfer across cell membranes
6470211, Jun 03 1997 UAB Research Foundation Method and apparatus for treating cardiac arrhythmia
6482619, Jul 21 1999 The Regents of the University of California Cell/tissue analysis via controlled electroporation
6493592, Dec 01 1999 MEAGAN MEDICAL, INC Percutaneous electrical therapy system with electrode position maintenance
6500173, Jul 18 1996 Arthrocare Corporation Methods for electrosurgical spine surgery
6526320, Nov 16 1998 United States Surgical Corporation Apparatus for thermal treatment of tissue
6562604, Jul 21 1999 The Regents of the University of California Controlled electroporation and mass transfer across cell membranes
6607529, Jun 19 1995 VIDAMED, INC Electrosurgical device
6611706, Nov 09 1998 Syneron Medical Ltd Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
6613211, Aug 27 1999 Monogram Biosciences, Inc Capillary electrokinesis based cellular assays
6627421, Apr 13 1999 CEREVAST THERAPEUTICS, INC Methods and systems for applying multi-mode energy to biological samples
6653091, Sep 30 1998 Lifescan IP Holdings, LLC Method and device for predicting physiological values
6669691, Jul 18 2000 Boston Scientific Scimed, Inc Epicardial myocardial revascularization and denervation methods and apparatus
6692493, Feb 11 1998 Cosman Company, Inc.; The General Hospital Corporation Method for performing intraurethral radio-frequency urethral enlargement
6697669, Jul 13 1998 GENETRONICS, INC Skin and muscle-targeted gene therapy by pulsed electrical field
6697670, Aug 17 2001 AngioDynamics, Inc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
6702808, Sep 28 2000 Syneron Medical Ltd Device and method for treating skin
6795728, Aug 17 2001 AngioDynamics, Inc Apparatus and method for reducing subcutaneous fat deposits by electroporation
6801804, May 03 2002 ACIONT, INC Device and method for monitoring and controlling electrical resistance at a tissue site undergoing iontophoresis
6865416, May 08 1998 OncoSec Medical Incorporated Electrically induced vessel vasodilation
6892099, Feb 08 2001 AngioDynamics, Inc Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
6912417, Apr 05 2002 ICHOR MEDICAL SYSTEMS, INC Method and apparatus for delivery of therapeutic agents
6927049, Jul 21 1999 Regents of the University of California, The Cell viability detection using electrical measurements
6962587, Jul 25 2000 AngioDynamics, Inc Method for detecting and treating tumors using localized impedance measurement
6972014, Jan 04 2003 Varian Medical Systems, Inc Open system heat exchange catheters and methods of use
6994706, Aug 13 2001 AngioDynamics, Inc Apparatus and method for treatment of benign prostatic hyperplasia
7053063, Jul 21 1999 The Regents of the University of California Controlled electroporation and mass transfer across cell membranes in tissue
7063698, Jun 14 2002 Atricure, Inc Vacuum coagulation probes
7130697, Aug 13 2002 AngioDynamics, Inc Apparatus and method for the treatment of benign prostatic hyperplasia
7211083, Mar 17 2003 AngioDynamics, Inc Apparatus and method for hair removal by electroporation
7267676, Mar 17 2003 AngioDynamics, Inc Method for hair removal by electroporation
20010044596,
20020010491,
20020055731,
20020077676,
20020099323,
20020138117,
20020193831,
20030009110,
20030060856,
20030088189,
20030130711,
20030170898,
20030208200,
20030225360,
20040019371,
20040059389,
20040146877,
20040153057,
20040243107,
20040267189,
20050043726,
20050049541,
20050165393,
20050171523,
20050171574,
20050182462,
20050261672,
20050288730,
20060015147,
20060025760,
20060079883,
20060121610,
20060212078,
20060217703,
20060264752,
20070043345,
20070118069,
20080052786,
DE4000893,
DE863111,
EP378132,
EP935482,
WO20554,
WO107583,
WO107584,
WO107585,
WO181533,
WO4037341,
WO9639531,
//////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Oct 01 2009AngioDynamics, Inc.(assignment on the face of the patent)
May 22 2012AngioDynamics, IncJPMORGAN CHASE BANK, N A , AS ADMINISTRATIVE AGENTSECURITY AGREEMENT0282600329 pdf
Sep 19 2013AngioDynamics, IncJPMORGAN CHASE BANK, N A , AS ADMINISTRATIVE AGENTSECURITY AGREEMENT0313150720 pdf
Sep 19 2013JPMORGAN CHASE BANK N A , AS ADMINISTRATIVE AGENTAngioDynamics, IncRELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS 0313150361 pdf
Nov 07 2016AngioDynamics, IncJPMORGAN CHASE BANK, N A , AS ADMINISTRATIVE AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0406130049 pdf
Nov 07 2016JPMORGAN CHASE BANK, N A , AS ADMINISTRATIVE AGENTAngioDynamics, IncRELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS 0406880540 pdf
Jun 03 2019AngioDynamics, IncJPMORGAN CHASE BANK, N A , AS ADMINISTRATIVE AGENTCONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS0493710657 pdf
Aug 30 2022AngioDynamics, IncJPMORGAN CHASE BANK, N A , AS ADMINISTRATIVE AGENTSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0613600668 pdf
Aug 30 2022JPMORGAN CHASE BANK, N A , AS ADMINISTRATIVE AGENTAngioDynamics, IncRELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS 0613630446 pdf
Jun 08 2023JPMORGAN CHASE BANK, N A , AS ADMINISTRATIVE AGENTAngioDynamics, IncRELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS 0639400362 pdf
Date Maintenance Fee Events
Aug 12 2015M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Oct 11 20144 years fee payment window open
Apr 11 20156 months grace period start (w surcharge)
Oct 11 2015patent expiry (for year 4)
Oct 11 20172 years to revive unintentionally abandoned end. (for year 4)
Oct 11 20188 years fee payment window open
Apr 11 20196 months grace period start (w surcharge)
Oct 11 2019patent expiry (for year 8)
Oct 11 20212 years to revive unintentionally abandoned end. (for year 8)
Oct 11 202212 years fee payment window open
Apr 11 20236 months grace period start (w surcharge)
Oct 11 2023patent expiry (for year 12)
Oct 11 20252 years to revive unintentionally abandoned end. (for year 12)